The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice
- 16 August 2021
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 38 (5) , 441-449
Abstract
Osteosarcoma is the most common form of primary bone cancer and frequently metastasizes to the lungs. Current therapies fail to successfully treat over two thirds of patients with metastatic osteosarcoma, so there is an urgent imperative to develop therapies that effectively target established metastases. Smac mimetics are drugs that work by inhibiting the pro-survival activity of IAP proteins such as cIAP1 and cIAP2, which can be overexpressed in osteosarcomas. In vitro, osteosarcoma cells are sensitive to a range of Smac mimetics in combination with TNFα. This sensitivity has also been demonstrated in vivo using the Smac mimetic LCL161, which inhibited the growth of subcutaneous and intramuscular osteosarcomas. Here, we evaluated the efficacy of LCL161 using mice bearing osteosarcoma metastases without the presence of a primary tumor, modeling the scenario in which a patient’s primary tumor had been surgically removed. We demonstrated the ability of LCL161 as a single agent and in combination with doxorubicin to inhibit the growth of, and in some cases eliminate, established pulmonary osteosarcoma metastases in vivo. Resected lung metastases from treated and untreated mice remained sensitive to LCL161 in combination with TNFα ex vivo. This suggested that there was little to no acquired resistance to LCL161 treatment in surviving osteosarcoma cells and implied that tumor microenvironmental factors underlie the observed variation in responses to LCL161.Keywords
Funding Information
- The Kids’ Cancer Project
- Cancer Council Victoria (APP1145995)
- Tour de Cure
This publication has 30 references indexed in Scilit:
- TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated stateOncogene, 2013
- Serum tumor markers in pediatric osteosarcoma: a summary reviewClinical Sarcoma Research, 2012
- A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical EraSarcoma, 2012
- Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effectsThe Lancet Oncology, 2010
- The Epidemiology of Osteosarcoma2009
- MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma ProgressionCancer Research, 2009
- Drug Resistance and the Solid Tumor MicroenvironmentJNCI: Journal of the National Cancer Institute, 2007
- Brain metastasis in pediatric extracranial solid tumors: survey and literature reviewJournal of Neuro-Oncology, 2005
- Smac/DIABLO Selectively Reduces the Levels of c-IAP1 and c-IAP2 but Not That of XIAP and Livin in HeLa CellsJournal of Biological Chemistry, 2004
- Cytotoxic Cs in Immunodeficient Athymic MiceImmunopharmacology and Immunotoxicology, 1994